Table 1: Cases of potential
lipodystrophy syndrome* associated with antiretroviral
drugs reported to the CADRMP up to Aug. 31, 2001
|
Case
|
Age/ sex
|
Reported
clinical
reactions† |
Reported metabolic
reactions†
|
Concomitant drugs
|
Duration
of treatment
|
Suspect drug reported
|
|
|
PI
|
NRTI
|
|
| 1 |
56/F
|
Lipodystrophy |
Diabetes
mellitus |
Lamivudine,
nadolol, Prevacid, Zoloft |
NA
|
-
|
Stavudine
|
| 2 |
33/M
|
Fat
disorder |
Hyperglycemia |
Lamivudine,
stavudine |
26 wk
|
Indinavir
|
-
|
| 3 |
44/M
|
Fat
disorder |
Hyperglycemia,
hypertriglyceridemia |
Nelfinavir |
NA
|
Saquinavir
|
-
|
| 4 |
49/M
|
Lipodystrophy,
enlarged abdomen |
Hypertriglyceridemia |
Azithromycin,
lamivudine, saquinavir, stavudine |
Continuing
|
Ritonavir
|
-
|
Note:
CADRMP = Canadian Adverse Drug Reaction Monitoring Program, PI = protease inhibitor,
NRTI = nucleoside reverse transcriptase inhibitor, NA = not available.
*
Met working case definition: at least one clinical feature and at least
one metabolic abnormality, and no AIDS-defining event or other severe clinical
illness or use of anabolic steroids, glucocorticoids or immune modulators
within 3 months of assessment.
†
Based on the "preferred term" of the World Health Organization Adverse
Reaction Dictionary (WHOART).
|
